FDA Investigator

Jiangsong Jiang

Latest inspection on record: Shanghai, China, May 2026 · records back to 2024

Human Drugs

FDA inspection record · Last updated July 12, 2026

Overview

  • 6 inspections across 6 sites are on record.
  • 0 Form 483 observations are attributed to this investigator.
  • Most recent recorded activity is 2026-05-20.

At a glance

Inspections

6

Sites

6

Observations

0

Career since

Mar 2024

Recent inspections

Most recent inspections in the published record.

SiteDateCategoryForm 483
Shanghai Henlius Biopharmaceuticals Co., Ltd.20 May 2026Human DrugsOn file
Regeneron Pharmaceuticals, Inc.16 Jan 2026Human DrugsOn file
DR. REDDY'S LABORATORIES LTD12 Sep 2025Human DrugsOn file
Bio-Thera Solutions, Ltd.17 Jan 2025Human DrugsOn file
Suzhou Suncadia Biopharmaceuticals Co., Ltd6 Jan 2025Human DrugsOn file

Sites inspected

Regeneron Pharmaceuticals, Inc.East Greenbush, United States1 insp.
DR. REDDY'S LABORATORIES LTDBachupally, India1 insp.
Bio-Thera Solutions, Ltd.Guangzhou, China1 insp.

Co-investigators

Investigators who share inspections with this person.

Yiwei Li2 shared
Xiaoshi Wang1 shared
Jie He1 shared
Baikuntha Aryal1 shared

Full investigator report

Get the verbatim findings behind Jiangsong Jiang's inspection record

Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.

  • New inspections and Form 483s, mapped to the CFR citation
  • Warning letter outcomes, and the citation patterns they repeat
  • Their co-investigators, so no surprises about who shows up on site